Business Context and Reporting Period
This Form 8-K Current Report was filed by EyeGate Pharmaceuticals, Inc. (trading symbol: EYEG) on December 30, 2019, reporting events occurring on December 31, 2019. The registrant is a Delaware corporation and an emerging growth company. The filing details the entry into a material definitive agreement for a private placement of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of 500,000 shares of common stock.
- Purchase Price: $10.00 per share.
- Gross Proceeds: Expected total of $5.0 million.
- Net Proceeds: Approximately $4.5 million after deducting placement agent fees, expenses, and estimated offering costs.
- Placement Agent Fees: 7% of gross proceeds plus a 1% management fee.
- Other Costs: $75,000 in non-accountable expenses and $10,000 in clearing fees.
- Placement Agent Warrants: Warrants to purchase up to 25,000 shares (5% of shares sold) at an exercise price of $12.50 per share, exercisable for five years.
Material Changes and Use of Proceeds
The filing does not provide comparative financial data (revenue, profit, or cash flow) for the prior period as this is a current report regarding a specific transaction rather than a periodic financial statement. The material change is the anticipated increase in liquidity through the issuance of new equity. The Company intends to use the net proceeds to support operations, including clinical trials, working capital, and general corporate purposes. Proceeds may also be used for the acquisition or in-licensing of products or technologies, though no specific acquisition is currently contemplated.
Outlook, Risks, and Unusual Items
Closing Conditions: The transaction closing is expected on or about January 3, 2020, subject to customary closing conditions.
Regulatory Status: The shares are being offered pursuant to an effective shelf registration statement on Form S-3 filed in May 2019. A prospectus supplement will be filed with the SEC.
Risk Disclosure: The filing notes that representations and warranties in the Purchase Agreement are for risk allocation between parties and may not reflect materiality standards viewed by stockholders. Information regarding these representations may change after the agreement date.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected January 3, 2020) and confirmation of fund receipt.
- Review the filed prospectus supplement for any updated terms or conditions.
- Monitor the Company's subsequent filings for specific allocation of the $4.5 million net proceeds among clinical trials, working capital, or potential acquisitions.
- Check for any dilution impact on existing shareholders resulting from the issuance of 500,000 new shares and 25,000 warrant shares.